In pancreatic cancer, HLA‐B modulates ITGB1 expression, influencing migration and transmembrane signaling [82], while its altered expression impairs tumor antigen recognition in cervical cancer [83] and affects immune checkpoint inhibitor efficacy in gastrointestinal malignancies [84]. Here, HLA-B is linked to cervical carcinoma.